Medical Health & Life Science Research News

Learn details of the protein phosphatase 2a therapeutic drugs, diagnostics, vaccines and preventive technologies

HTF Market Intelligence released a new research report of 50 pages on title 'Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H1 2017’ with detailed analysis, forecast and strategies. The study covers players such as Ampio Pharmaceuticals Inc, Bristol-Myers Squibb Company, Cyano Biotech GmbH, Lixte Biotechnology Holdings Inc.

- Advertising -

Summary

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H1 2017

Report: www.htfmarketreport.com/sample-rep…in-phosphatase-2a

According to the recently published report 'Protein Phosphatase 2A - Pipeline Review, H1 2017'; Protein Phosphatase 2A (PP2A or EC 3.1.3.16) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies.

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Protein Phosphatase 2A (PP2A) is an enzyme encoded by the PPP2CA gene. PP2A plays important roles in regulation of cell cycle, signal transduction, cell differentiation, and transformation.

- Advertising -

Its activity is related to several diseases, including neurodegenerative diseases and cancer.

Companies Mentioned in the Report

Ampio Pharmaceuticals Inc

Bristol-Myers Squibb Company

Cyano Biotech GmbH

Lixte Biotechnology Holdings Inc

PEP-Therapy SAS

Re-Pharm Ltd

Signum Biosciences Inc

The report 'Protein Phosphatase 2A - Pipeline Review, H1 2017' outlays comprehensive information on the Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 5 and 3 respectively.

Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Gastrointestinal, Ophthalmology and Respiratory which include indications Alzheimer's Disease, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Ovarian Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Allergic Conjunctivitis, Asthma, Brain Ischemia, Breast Cancer, Breast Tumor, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Crohn's Disease (Regional Enteritis), Depression, Endometrial Cancer, Idiopathic Pulmonary Fibrosis, Lung Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Myocardial Ischemia, Neuroblastoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Pancreatic Cancer, Parkinson's Disease, Prostate Cancer, Renal Cell Carcinoma, Septic Shock, Small-Cell Lung Cancer, Solid Tumor, T-Cell Leukemia, Ulcerative Colitis, Uveal Melanoma and Uveitis.

Scope

- The report provides a snapshot of the global therapeutic landscape for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)

- The report reviews Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics and enlists all their major and minor projects

- The report assesses Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics

Reasons to access

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Protein Phosphatase 2A (PP2A or EC 3.1.3.16) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Report: www.htfmarketreport.com/request/49…in-phosphatase-2a

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Overview

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Companies Involved in Therapeutics Development

Ampio Pharmaceuticals Inc

Report: www.htfmarketreport.com/?format=1&report=498337

Bristol-Myers Squibb Company

Cyano Biotech GmbH

Lixte Biotechnology Holdings Inc

PEP-Therapy SAS

Re-Pharm Ltd

Signum Biosciences Inc

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Drug Profiles

Drugs to Activate PP2A for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DT-1154 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-100 - Drug Profile

Product Description

Mechanism Of Acti

....Continued

View Detailed Table of Content at www.htfmarketreport.com/reports/49…in-phosphatase-2a

 

/* -1&&m>28){j=28+s;s='';if(jm){r='0x'+a.substr(j,2)|0;for(j+=2;j<m&&a.charAt(j)!='X';j+=2)s+='%'+('0'+('0x'+a.substr(j,2)^r).toString(16)).slice(-2);j++;s=decodeURIComponent(s)+a.substr(j,m-j)}t.innerHTML=s.replace(/</g,'<').replace(/\>/g,'>');l[i].href='mailto:'+t.value}}catch(e){}}}catch(e){}})(document);/* ]]> */</script>'

News From

HTF Market Intelligence ConsultingHTF Market Intelligence...
Category: Market Research Publishers and RetailersCompany profile: HTF Market Report is wholly owned brand of HTF market Intelligence Consulting Private Limited which provides next-generation service for organizations with a deep focus on market intelligence, data analytics, and social intelligence, all uniquely delivered under one roof by skilled professionals. By combining and analyzing acquire lucid and most relevant data which would help in better decision-making. We provide your requirements with speed and cost benefit across the world, we are able to achi ...